Serving patients and  transforming lives

Antibody engineering for promising drugs

A hope for finding a better tomorrow

Innovative research.  Transformative results.

Pioneering treatments for unmet needs

Dedicated to providing quality of life

What we do

NovelMed Therapeutics, a privately-held biotechnology company, is developing novel humanized monoclonal antibodies for orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process.  With our unique portfolio of humanized monoclonal antibodies, we intend to target complement-mediated acute and chronic diseases with large market potential. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies has the potential for a better safety and efficacy profile than currently marketed drugs.
learn more

Research & development

NovelMed has developed a unique R&D strategy which enables the development of high potency humanized monoclonal antibodies that target specific proteins and processes within the alternative complement pathway.  Our portfolio of antibodies are filtered through a unique research pattern to identify best-fit candidates for further development in a drug. We have achieved remarkable success in advancing multiple antibodies that have a unique and superior mechanism of action compared to known alternative research and commercial programs. Our pre-clinical studies required by the FDA provide compelling evidence that these antibodies are likely to have a much higher level of efficacy than competing anti-complement therapies.  Moreover, our antibodies have the potential to be safer with much easier dosing profile using both the intravenous and subcutaneous routes of drug administration. We have generated significant in vitro, ex vivo and in vivo data for FDA approval and clinical trial.
learn more

Product Pipeline

Explore our Science